Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
National Cancer Institute®
Last Modified: November 21, 2001
1
UI - 21262733
AU - Bougeard G; Limacher JM; Martin C; Charbonnier F; Killian A; Delattre O;
TI -
Longy M; Jonveaux P; Fricker JP; Stoppa-Lyonnet D; Flaman JM; Frebourg T
Detection of 11 germline inactivating TP53 mutations and absence of
TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni
or Li-Fraumeni-like syndrome.
SO - J Med Genet 2001 Apr;38(4):253-7
2
UI - 21300246
AU - Malkin D
TI -
The role of p53 in human cancer.
SO - J Neurooncol 2001 Feb;51(3):231-43
AD - Department of Pediatrics, The Hospital for Sick Children, University of
Toronto, Ontario, Canada. david.malkin@sickkids.on.ca
In the two decades since its original discovery, p53 has found a
singularly prominent place in our understanding of human cancer.
Although the biochemistry of p53 has been worked out in some detail, our
knowledge of the biologic consequences of p53 dysfunction is still quite
rudimentary. Over the next several years, it will be important to
determine how best to harness the complex properties of p53's ability to
induce cellular growth arrest and cell death to generate novel,
effective approaches to cancer therapy. Furthermore, a clearer
appreciation of the direct interaction of epigenetic factors with p53
will lead to development of strategies to inhibit tumour initiation and
progression. The next decade promises to offer exciting opportunities to
apply our vast knowledge of this intriguing tumor suppressor to clinical
advantage.
3
UI - 92341381
AU - Li FP; Garber JE; Friend SH; Strong LC; Patenaude AF; Juengst ET; Reilly
TI -
PR; Correa P; Fraumeni JF Jr
Recommendations on predictive testing for germ line p53 mutations among
cancer-prone individuals.
SO - J Natl Cancer Inst 1992 Aug 5;84(15):1156-60
AD - Dana-Farber Cancer Institute, Boston, Mass.
4
UI - 93278969
AU - Evans G
TI -
Ethical issues: the geneticist's view point.
SO - Dis Markers 1992 Jul-Aug;10(4):199-203; discussion 211-28
AD - Department of Medical Genetics, St Mary's Hospital, Manchester.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Ms. Bruning talks about working in development for a cancer center and how this translates to hope in cancer care. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

